Intranasal insulin protects against substantia nigra dopaminergic neuronal loss and alleviates motor deficits induced by 6-OHDA in rats

Neuroscience

Volumn 318, Issue , 2016, Pages 157-165

  Pang, Y ^a   Lin, S ^a   Wright, C ^a   Shen, J ^a   Carter, K ^a   Bhatt, A ^a   Fan, L W ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Dopaminergic neurons; Insulin; Neurotrophin; Parkinson's disease; Striatum; Substantia nigra

Indexed keywords

GLUCOSE; RECOMBINANT HUMAN INSULIN; DOPAMINE; INSULIN; NEUROPROTECTIVE AGENT; OXIDOPAMINE;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CELL LOSS; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG EFFECT; GLUCOSE BLOOD LEVEL; LOCOMOTION; MALE; MOTOR DYSFUNCTION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA PARS COMPACTA; ANIMAL; CHEMICALLY INDUCED; CORPUS STRIATUM; DRUG EFFECTS; METABOLISM; NERVE DEGENERATION; PATHOLOGY; SPRAGUE DAWLEY RAT; SUBSTANTIA NIGRA;

ANIMALS; BEHAVIOR, ANIMAL; CORPUS STRIATUM; DOPAMINE; INSULIN; MALE; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; RATS, SPRAGUE-DAWLEY; SUBSTANTIA NIGRA;

EID: 84961297546     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2016.01.020     Document Type: Article

References (47)

1. Adzovic L., Lynn A.E., D'Angelo H.M., Crockett A.M., Kaercher R.M., Royer S.E., Hopp S.C., Wenk G.L. Insulin improves memory and reduces chronic neuroinflammation in the hippocampus of young but not aged brains. J Neuroinflammation 2015, 12:63.
2. Banks W.A., Owen J.B., Erickson M.A. Insulin in the brain: there and back again. Pharmacol Ther 2012, 136:82-93.
3. Beccaria K., Canney M., Goldwirt L., Fernandez C., Piquet J., Perier M.C., Lafon C., Chapelon J.Y., Carpentier A. Ultrasound-induced opening of the blood-brain barrier to enhance temozolomide and irinotecan delivery: an experimental study in rabbits. J Neurosurg 2015, 13:1-9.
4. Begley D.J. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Ther 2004, 104:29-45.
5. Bender T.S., Migliore M.M., Campbell R.B., John Gatley S., Waszczak B.L. Intranasal administration of glial-derived neurotrophic factor (GDNF) rapidly and significantly increases whole-brain GDNF level in rats. Neuroscience 2015, 303:569-576.
6. Benedict C., Hallschmid M., Hatke A., Schultes B., Fehm H.L., Born J., Kern W. Intranasal insulin improves memory in humans. Psychoneuroendocrinology 2004, 29:1326-1334.
7. Bove J., Prou D., Perier C., Przedborski S. Toxin-induced models of Parkinson's disease. NeuroRx 2005, 2:484-494.
8. Cai Z., Fan L.W., Lin S., Pang Y., Rhodes P.G. Intranasal administration of insulin-like growth factor-1 protects against lipopolysaccharide-induced injury in the developing rat brain. Neuroscience 2011, 194:195-207.
9. d'Anglemont de Tassigny X., Pascual A., Lopez-Barneo J. GDNF-based therapies, GDNF-producing interneurons, and trophic support of the dopaminergic nigrostriatal pathway. Implications for Parkinson's disease. Front Neuroanat 2015, 9:10.
10. De Ryck M., Van Reempts J., Duytschaever H., Van Deuren B., Clincke G. Neocortical localization of tactile/proprioceptive limb placing reactions in the rat. Brain Res 1992, 573:44-60.
11. Djupesland P.G., Mahmoud R.A., Messina J.C. Accessing the brain: the nose may know the way. J Cereb Blood Flow Metab 2013, 33:793-794.
12. Duarte A.I., Moreira P.I., Oliveira C.R. Insulin in central nervous system: more than just a peripheral hormone. J Aging Res 2012, 2012:384017.
13. Fernandez A.M., Torres-Aleman I. The many faces of insulin-like peptide signalling in the brain. Nat Rev Neurosci 2012, 13:225-239.
14. Figlewicz D.P., Evans S.B., Murphy J., Hoen M., Baskin D.G. Expression of receptors for insulin and leptin in the ventral tegmental area/substantia nigra (VTA/SN) of the rat. Brain Res 2003, 964:107-115.
15. Fleming S.M., Zhu C., Fernagut P.O., Mehta A., DiCarlo C.D., Seaman R.L., Chesselet M.F. Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone. Exp Neurol 2004, 187:418-429.
16. Fletcher L., Kohli S., Sprague S.M., Scranton R.A., Lipton S.A., Parra A., Jimenez D.F., Digicaylioglu M. Intranasal delivery of erythropoietin plus insulin-like growth factor-I for acute neuroprotection in stroke. Laboratory investigation. J Neurosurg 2009, 111:164-170.
17. Freiherr J., Hallschmid M., Frey W.H., Brunner Y.F., Chapman C.D., Holscher C., Craft S., De Felice F.G., Benedict C. Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence. CNS Drugs 2013, 27:505-514.
18. Hadaczek P., Yamashita Y., Mirek H., Tamas L., Bohn M.C., Noble C., Park J.W., Bankiewicz K. The "perivascular pump" driven by arterial pulsation is a powerful mechanism for the distribution of therapeutic molecules within the brain. Mol Ther 2006, 14:69-78.
19. Hegarty S.V., O'Keeffe G.W., Sullivan A.M. Neurotrophic factors: from neurodevelopmental regulators to novel therapies for Parkinson's disease. Neural Regen Res 2014, 9:1708-1711.
20. Jeschke M.G., Klein D., Bolder U., Einspanier R. Insulin attenuates the systemic inflammatory response in endotoxemic rats. Endocrinology 2004, 145:4084-4093.
21. Kalia L.V., Kalia S.K., Lang A.E. Disease-modifying strategies for Parkinson's disease. Mov Disord 2015, 30:1442-1450.
22. Kamei N., Takeda-Morishita M. Brain delivery of insulin boosted by intranasal coadministration with cell-penetrating peptides. J Control Release 2015, 197:105-110.
23. Kim S.J., Han Y. Insulin inhibits AMPA-induced neuronal damage via stimulation of protein kinase B (Akt). J Neural Transm 2005, 112:179-191.
24. Lin S., Fan L.W., Rhodes P.G., Cai Z. Intranasal administration of IGF-1 attenuates hypoxic-ischemic brain injury in neonatal rats. Exp Neurol 2009, 217:361-370.
25. Ling Z., Chang Q.A., Tong C.W., Leurgans S.E., Lipton J.W., Carvey P.M. Rotenone potentiates dopamine neuron loss in animals exposed to lipopolysaccharide prenatally. Exp Neurol 2004, 190:373-383.
26. Liu Q., Shen Y., Chen J., Gao X., Feng C., Wang L., Zhang Q., Jiang X. Nose-to-brain transport pathways of wheat germ agglutinin conjugated PEG-PLA nanoparticles. Pharm Res 2012, 29:546-558.
27. Lochhead J.J., Thorne R.G. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev 2012, 64:614-628.
28. Lopes C., Ribeiro M., Duarte A.I., Humbert S., Saudou F., Pereira de Almeida L., Hayden M., Rego A.C. IGF-1 intranasal administration rescues Huntington's disease phenotypes in YAC128 mice. Mol Neurobiol 2014, 49:1126-1142.
29. Marks D.R., Tucker K., Cavallin M.A., Mast T.G., Fadool D.A. Awake intranasal insulin delivery modifies protein complexes and alters memory, anxiety, and olfactory behaviors. J Neurosci 2009, 29:6734-6751.
30. Migliore M.M., Ortiz R., Dye S., Campbell R.B., Amiji M.M., Waszczak B.L. Neurotrophic and neuroprotective efficacy of intranasal GDNF in a rat model of Parkinson's disease. Neuroscience 2014, 274:11-23.
31. Negron A.L., Beymer M., Yu G., Warren K.A., Acosta-Martinez M. Prolonged hyperglycemia & hyperinsulinemia increases BDNF mRNA expression in the posterior ventromedial hypothalamus and the dorsomedial hypothalamus of fed female rats. Neuroscience 2015, 303:422-432.
32. Ozsoy Y., Gungor S., Cevher E. Nasal delivery of high molecular weight drugs. Molecules 2009, 14:3754-3779.
33. Pardeshi C.V., Belgamwar V.S. Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood-brain barrier: an excellent platform for brain targeting. Expert Opin Drug Deliv 2013, 10:957-972.
34. Paxinos G., Watson C., Pennisi M., Topple A. Bregma, lambda and the interaural midpoint in stereotaxic surgery with rats of different sex, strain and weight. J Neurosci Methods 1985, 13:139-143.
35. Reger M.A., Watson G.S., Green P.S., Baker L.D., Cholerton B., Fishel M.A., Plymate S.R., Cherrier M.M., Schellenberg G.D., Frey W.H., Craft S. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J Alzheimers Dis 2008, 13:323-331.
36. Ribeiro M., Rosenstock T.R., Oliveira A.M., Oliveira C.R., Rego A.C. Insulin and IGF-1 improve mitochondrial function in a PI-3K/Akt-dependent manner and reduce mitochondrial generation of reactive oxygen species in Huntington's disease knock-in striatal cells. Free Radic Biol Med 2014, 74:129-144.
37. Rodrigues T.M., Jeronimo-Santos A., Outeiro T.F., Sebastiao A.M., Diogenes M.J. Challenges and promises in the development of neurotrophic factor-based therapies for Parkinson's disease. Drugs Aging 2014, 31:239-261.
38. Schallert T., Woodlee M.T. Motor systems: orienting and placing. The behaviour of the laboratory rat: a handbook with tests 2005, 129-140. Oxford University Press, New York. I.Q. Whishaw, B. Kolb (Eds.).
39. Spielman L.J., Bahniwal M., Little J.P., Walker D.G., Klegeris A. Insulin modulates in vitro secretion of cytokines and cytotoxins by human glial cells. Curr Alzheimer Res 2015, 12:684-693.
40. Sun X., Yao H., Douglas R.M., Gu X.Q., Wang J., Haddad G.G. Insulin/PI3K signaling protects dentate neurons from oxygen-glucose deprivation in organotypic slice cultures. J Neurochem 2010, 112:377-388.
41. Thorne R.G., Hanson L.R., Ross T.M., Tung D., Frey W.H. Delivery of interferon-beta to the monkey nervous system following intranasal administration. Neuroscience 2008, 152:785-797.
42. Thorne R.G., Pronk G.J., Padmanabhan V., Frey W.H. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 2004, 127:481-496.
43. Tillerson J.L., Cohen A.D., Caudle W.M., Zigmond M.J., Schallert T., Miller G.W. Forced nonuse in unilateral parkinsonian rats exacerbates injury. J Neurosci 2002, 22:6790-6799.
44. Torres-Aleman I. Toward a comprehensive neurobiology of IGF-I. Dev Neurobiol 2010, 70:384-396.
45. Unger J.W., Moss A.M., Livingston J.N. Immunohistochemical localization of insulin receptors and phosphotyrosine in the brainstem of the adult rat. Neuroscience 1991, 42:853-861.
46. Woodlee M.T., Asseo-Garcia A.M., Zhao X., Liu S.J., Jones T.A., Schallert T. Testing forelimb placing "across the midline" reveals distinct, lesion-dependent patterns of recovery in rats. Exp Neurol 2005, 191:310-317.
47. Zhao C.S., Puurunen K., Schallert T., Sivenius J., Jolkkonen J. Effect of cholinergic medication, before and after focal photothrombotic ischemic cortical injury, on histological and functional outcome in aged and young adult rats. Behav Brain Res 2005, 156:85-94.